Jardiance vs Tresiba Real-World Evidence Comparison

How Each Drug Actually Lowers Blood Sugar

Jardiance and Tresiba lower glucose through mechanisms so different they almost cannot be directly compared on pharmacology alone. Jardiance blocks sodium-glucose cotransporter-2 (SGLT2) in the proximal tubule of the kidney, forcing roughly 70 grams of glucose into the urine every day regardless of insulin levels. Tresiba works by binding insulin receptors across fat, muscle, and liver tissue, suppressing hepatic glucose output and enabling cellular glucose uptake. One drug bypasses insulin entirely; the other is insulin.

SGLT2 Inhibition: What Jardiance Does at the Kidney

Empagliflozin achieves its glucose-lowering effect independent of beta-cell function, which means it remains active even in patients with significant insulin secretory deficiency. The FDA label for Jardiance notes a mean HbA1c reduction of approximately 0.7 to 0.8% as monotherapy and 0.6 to 0.9% when added to metformin in phase 3 trials [1]. Because the mechanism is renal, efficacy decreases as estimated glomerular filtration rate (eGFR) falls. The current FDA label contraindicates Jardiance for glycemic control when eGFR is <30 mL/min/1.73 m² [1].

The renal glucose loss also produces osmotic diuresis and modest natriuresis, effects that translate into blood-pressure reductions of 3 to 5 mmHg systolic and plasma-volume contraction of roughly 5 to 7% in clinical studies [2].

Basal Insulin Replacement: What Tresiba Does Over 42 Hours

Insulin degludec forms soluble multihexamer chains at the subcutaneous injection site that slowly dissociate into active monomers over time. This process creates a half-life exceeding 25 hours and a duration of action beyond 42 hours, longer than insulin glargine U300 (roughly 36 hours) and considerably longer than glargine U100 (roughly 24 hours) [3]. The clinical result is a flatter, more predictable pharmacodynamic profile with a day-to-day variability coefficient roughly four times lower than glargine U100 in crossover clamp studies [3].

Tresiba's starting dose in insulin-naive type 2 diabetes patients is typically 10 units once daily, titrated by 2 units every 3 days until fasting glucose reaches 80 to 100 mg/dL. The FDA label permits flexible dosing timing with a minimum 8-hour interval between injections without meaningful loss of glycemic control [4].

Landmark Trials: The Evidence That Changed Practice

EMPA-REG OUTCOME: Jardiance and Cardiovascular Death

The EMPA-REG OUTCOME trial enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease, randomizing them to empagliflozin 10 mg, empagliflozin 25 mg, or placebo on top of standard care [5]. At a median follow-up of 3.1 years, the primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 10.5% of the empagliflozin group versus 12.1% in the placebo group, a 14% relative risk reduction (hazard ratio 0.86; 95% CI 0.74 to 0.99; P<0.001 for noninferiority, P=0.04 for superiority) [5].

The cardiovascular mortality signal was striking. Death from cardiovascular causes fell 38% (HR 0.62; 95% CI 0.49 to 0.77), and hospitalization for heart failure dropped 35% (HR 0.65; 95% CI 0.50 to 0.85) [5]. These benefits appeared within the first few months of treatment, far too quickly to attribute to glucose lowering alone, which led researchers to hypothesize that hemodynamic and renal effects (diuresis, reduced preload) were the primary drivers.

As the NEJM editorial accompanying the trial stated, "The magnitude of the reduction in cardiovascular death with empagliflozin... Suggests a mechanism of action beyond glucose lowering" [5].

DEVOTE: Tresiba and Severe Hypoglycemia

The DEVOTE trial enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk, randomizing them to insulin degludec or insulin glargine U100 on a treat-to-target protocol [6]. Severe hypoglycemia was a pre-specified secondary endpoint. Insulin degludec produced 40% fewer severe hypoglycemia events than glargine U100 (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001), with 53% fewer nocturnal severe hypoglycemia episodes (rate ratio 0.47; 95% CI 0.31 to 0.73) [6].

HbA1c reduction was equivalent between the two insulins (approximately 1.0% from baseline in both arms), confirming the hypoglycemia advantage was achieved without sacrificing glucose control [6]. Cardiovascular outcomes were noninferior to glargine U100 (HR 0.91; 95% CI 0.78 to 1.06), meeting the FDA's required cardiovascular safety threshold for new diabetes drugs [6].

Real-World Registry Evidence

Landmark randomized trials enroll selected populations. Real-world databases capture the messy reality of clinical practice.

A 2019 CVD-REAL 3 analysis pooling electronic health records from 13 countries compared SGLT2 inhibitors (predominantly empagliflozin in several participating regions) against other glucose-lowering drugs in over 215,000 patients [7]. Initiation of an SGLT2 inhibitor was associated with a 24% lower risk of all-cause mortality (HR 0.76; 95% CI 0.69 to 0.84) and a 29% lower risk of hospitalization for heart failure (HR 0.71; 95% CI 0.64 to 0.79) compared with other agents [7]. These associations held after propensity-score matching and were consistent across countries with different background therapy rates.

For insulin degludec, a 2020 real-world observational study using Danish registry data (N=3,723) found that patients switching from glargine U100 to degludec experienced a 27% reduction in hypoglycemia-related emergency department visits over a 12-month follow-up period [8]. HbA1c remained stable at follow-up, replicating the DEVOTE pattern in a community-care setting.

Glycemic Efficacy: Head-to-Head Numbers

No randomized trial has directly compared empagliflozin against insulin degludec in a single study, so cross-trial comparisons require caution. The table below uses FDA-label and key-trial data only.

| Parameter | Jardiance (Empagliflozin) | Tresiba (Insulin Degludec) | |---|---|---| | Mean HbA1c reduction (monotherapy or add-on) | 0.7 to 0.8% | 0.9 to 1.4% (dose-dependent) | | Fasting plasma glucose reduction | 20 to 30 mg/dL | 30 to 50 mg/dL (titration-dependent) | | Body weight | Down 2 to 3 kg | Up 2 to 4 kg | | Systolic blood pressure | Down 3 to 5 mmHg | Neutral | | Confirmed hypoglycemia risk | Very low (glucose-dependent mechanism) | Low-to-moderate (lowest of basal insulins) | | Severe hypoglycemia | Rare (<0.1% in monotherapy trials) | 1.5 events per 100 patient-years in DEVOTE |

For patients whose HbA1c sits above 9.5% and who need substantial glucose-lowering, Tresiba's dose-dependent efficacy typically achieves larger absolute HbA1c reductions than Jardiance alone. For patients with HbA1c in the 7.5 to 9.0% range who also carry established cardiovascular disease, Jardiance's cardiorenal benefits add value beyond what its glucose-lowering effect alone would justify.

Cardiovascular and Renal Outcomes: Where the Data Diverge

This is where the two drugs become most distinct clinically.

Jardiance: Proven Cardiorenal Protection

Beyond EMPA-REG OUTCOME, the EMPEROR-Reduced trial (N=3,730) demonstrated that empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% in patients with heart failure with reduced ejection fraction (HFrEF), including patients with and without diabetes [9]. The FDA subsequently approved Jardiance for heart failure reduction regardless of diabetes status in 2021 [1].

The EMPA-KIDNEY trial (N=6,609) showed empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% compared with placebo in patients with chronic kidney disease, including those with eGFR as low as 20 mL/min/1.73 m² [10]. These data pushed major cardiology and nephrology guidelines to recommend SGLT2 inhibitors early in the treatment pathway for patients with CKD or heart failure.

The 2023 American Diabetes Association Standards of Care state that SGLT2 inhibitors with proven cardiovascular benefit should be used in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk independent of their glucose-lowering effect [11].

Tresiba: Cardiovascular Safety Without Superiority

DEVOTE established cardiovascular noninferiority for insulin degludec but did not show superiority over glargine U100 for major adverse cardiovascular events [6]. Tresiba carries no FDA-approved indication for cardiovascular risk reduction. Its cardiorenal story is about safety, specifically, that achieving tight glycemic targets with degludec does not increase cardiovascular events the way some older insulin trials had suggested.

The severe hypoglycemia advantage does carry cardiovascular relevance. Severe hypoglycemia triggers sympathoadrenal activation, QTc prolongation, and arrhythmia risk. A 2013 analysis of the ORIGIN trial found that each severe hypoglycemia event was associated with a 2.1-fold increased risk of subsequent cardiovascular death (HR 2.08; 95% CI 1.27 to 3.40) [12]. Fewer severe hypoglycemia events with degludec therefore translates to a physiologically plausible, though not directly proven, downstream cardiovascular benefit.

Hypoglycemia Risk: A Critical Safety Comparison

Severe hypoglycemia is the most feared complication of insulin therapy and a significant driver of diabetes-related emergency visits. Jardiance's mechanism is inherently glucose-dependent: as blood glucose falls below roughly 180 mg/dL, SGLT2 becomes progressively occupied, reducing further glucose excretion. This built-in ceiling makes hypoglycemia from Jardiance monotherapy exceedingly rare [1].

Jardiance Hypoglycemia Profile

In EMPA-REG OUTCOME, confirmed hypoglycemia occurred in 8.3% of empagliflozin patients versus 5.8% of placebo patients, but this increase was driven entirely by concomitant sulfonylurea or insulin use [5]. Among patients not using insulin or sulfonylureas, hypoglycemia rates were statistically indistinguishable between empagliflozin and placebo [5].

Tresiba Hypoglycemia Profile

Insulin degludec's advantage over glargine U100 in DEVOTE was discussed above. A separate crossover clamp study (N=54) confirmed that at equivalent doses, degludec produced roughly 4-fold lower within-subject variability in glucose-lowering effect compared with glargine U100 [3]. Lower variability directly translates to fewer unexpected glucose nadirs, which is the proximate cause of most severe hypoglycemia episodes.

The 2023 ADA Standards of Care list insulin degludec as a preferred basal insulin in patients with a history of severe hypoglycemia or nocturnal hypoglycemia, specifically citing the DEVOTE evidence base [11].

Side Effects Beyond Glucose: What Real-World Patients Experience

Jardiance: Genitourinary and Volume Effects

Jardiance's most common adverse effects in both trial and real-world data are genital mycotic infections (approximately 5 to 10% in women, 3 to 5% in men) driven by glucosuria creating a favorable environment for fungal overgrowth [1]. A 2022 pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) found genital infections to be the most frequently reported adverse drug reaction for empagliflozin across all submitted reports [13].

Diabetic ketoacidosis (DKA) is a rare but serious adverse effect of SGLT2 inhibitors. The FDA issued a safety communication in 2015 highlighting euglycemic DKA risk, particularly in patients who fast, undergo surgery, or have undiagnosed type 1 diabetes [1]. Real-world incidence in type 2 diabetes patients is estimated at approximately 0.16 to 0.76 events per 1,000 patient-years [13].

Fournier's gangrene (necrotizing fasciitis of the perineum) has been reported with SGLT2 inhibitors as a class. The FDA added a warning in 2018; the absolute risk remains very low but is higher than in comparable diabetes drug classes [1].

Tresiba: Injection Site and Weight Considerations

The most common adverse effects of insulin degludec are hypoglycemia (covered above), injection-site reactions (lipohypertrophy with repeated same-site injections), and weight gain. The 2 to 4 kg weight gain seen with degludec across titration trials is consistent with the anabolic effects of insulin generally [4]. Patients switching from an oral agent like Jardiance to Tresiba should be counseled to expect this weight trajectory reversal.

Insulin degludec is contraindicated during hypoglycemia episodes and requires dose adjustments during illness, fasting, or changes in renal or hepatic function [4].

Switching From Jardiance to Tresiba: Clinical Considerations

Clinicians encountering a patient who needs to transition from Jardiance to Tresiba (or add Tresiba to Jardiance) should assess four domains before making a change.

When the Switch Is Appropriate

Jardiance alone becomes insufficient when HbA1c rises above 9.5 to 10% despite maximally tolerated oral and non-insulin injectable therapy, when beta-cell function has declined to the point that insulin secretagogue pathways are no longer viable, or when a patient is hospitalized and requires predictable parenteral glucose management. The 2023 ADA Standards of Care recommend initiating basal insulin when HbA1c remains above 10 to 12% or when symptoms of hyperglycemia are present regardless of prior oral therapy [11].

Patients on Jardiance who are initiating Tresiba for the first time should note that SGLT2 inhibitors increase the risk of euglycemic DKA during periods of carbohydrate restriction or illness. When Tresiba is added, providers may choose to continue Jardiance for its cardiorenal benefits at a reduced dose, but they should educate patients on sick-day rules and DKA symptoms.

Starting Dose When Adding Tresiba

For insulin-naive patients previously on Jardiance, Tresiba typically starts at 10 units subcutaneously once daily in the evening. The treat-to-target titration used in DEVOTE called for dose increases of 2 units every 3 days when fasting glucose exceeded 90 mg/dL on two consecutive measurements [6]. Target fasting glucose of 80 to 90 mg/dL is reasonable for most adults without hypoglycemia unawareness.

If Jardiance is continued alongside Tresiba, providers should reduce or eliminate any sulfonylureas to avoid additive hypoglycemia risk. Metformin can typically be continued without dose adjustment.

Monitoring After the Transition

Patients starting Tresiba after Jardiance should monitor fasting blood glucose daily for at least the first 4 to 6 weeks of titration. HbA1c should be rechecked at 3 months. Providers should also monitor for signs of volume retention, since discontinuing Jardiance removes its diuretic effect and some patients experience a modest rise in blood pressure or ankle edema within 4 to 8 weeks.

Cost, Access, and Real-World Adherence

List prices in the United States for Jardiance 10 mg (30 tablets) run approximately $650, $700 per month without insurance, while Tresiba 100 U/mL FlexTouch pens (5 pack, 300 units each) run approximately $480, $560 per month without insurance [14]. Both manufacturers offer patient assistance programs.

A 2021 claims-database analysis of medication persistence in type 2 diabetes found 12-month adherence rates of approximately 67% for SGLT2 inhibitors versus 58% for basal insulins across commercial insurance beneficiaries [15]. Injection aversion, titration burden, and hypoglycemia fear contributed to lower basal insulin persistence, a pattern that real-world clinicians frequently encounter.

Current Guideline Positioning

The 2024 American Association of Clinical Endocrinology (AACE) Comprehensive Type 2 Diabetes Algorithm places SGLT2 inhibitors with cardiovascular benefit (including empagliflozin) as the preferred add-on after metformin in patients with established cardiovascular disease, heart failure, or CKD [16]. Basal insulin is positioned as the preferred agent when HbA1c is significantly above target and non-insulin agents are insufficient. The two drugs therefore occupy adjacent, sometimes overlapping, tiers in the treatment pathway rather than directly competing tiers.

The American Heart Association's 2022 Scientific Statement on cardiovascular-kidney-metabolic syndrome explicitly names empagliflozin as a first-line agent for patients with type 2 diabetes and heart failure or CKD, citing a body of evidence that extends well beyond glucose control [17].

Insulin degludec carries a specific guideline recommendation in the ADA 2023 Standards of Care as the preferred basal insulin formulation for patients with recurrent severe hypoglycemia, given the DEVOTE evidence base [11].